Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Preferred Stock Liabilities: 2020-2021

  • Candel Therapeutics' Preferred Stock Liabilities was N/A to $26.6 million in Q2 2021 from the same period last year, while for Jun 2021 it was $26.6 million, marking a year-over-year change of. This contributed to the annual value of $26.6 million for FY2020, which is N/A change from last year.
  • As of Q2 2021, Candel Therapeutics' Preferred Stock Liabilities stood at $26.6 million, which was down 0.00% from $26.6 million recorded in Q4 2020.
  • In the past 5 years, Candel Therapeutics' Preferred Stock Liabilities ranged from a high of $26.6 million in Q4 2020 and a low of $26.6 million during Q4 2020.
  • Its 2-year average for Preferred Stock Liabilities is $26.6 million, with a median of $26.6 million in 2021.